Table 1.
Epidemiological, demographic, and clinicopathological outcomes of 56 patients diagnosed with uterine leiomyoma (LM) and 47 patients with leiomyosarcoma (LMS) from the experimental cohort.
| Characteristics | LMS | LM | |
|---|---|---|---|
| Demographic variables | Age | ||
| ≤30 years | - | 2 (3.57%) | |
| 31–40 years | 7 (14.89%) | 17 (30.36%) | |
| 41–50 years | 11 (23.41%) | 33 (58.93%) | |
| 51–60 years | 20 (42.55%) | 2 (3.57%) | |
| ≥61 years | 9 (19.15%) | - | |
| Not available (n) | - | 2 (3.57%) | |
| Median (years) | 53 | 44 | |
| Range (years | 35–75 | 28–55 | |
| Ethnicity | |||
| Caucasian | 36 (76.59%) | 41 (73.21%) | |
| African American | 1(2.13%) | 1 (1.79%) | |
| Latin | 4 (8.51%) | 6 (10.71%) | |
| Asian | 1(2.13%) | - | |
| Arabic | 1(2.13%) | - | |
| Not available | 4 (8.51%) | 8 (14.29%) | |
| Body mass index (kg/m2) | |||
| Median | 27.15 | 24 | |
| Range | 21.5–34.9 | 18.20–34.63 | |
| Not available (n) | 21 | 13 | |
| Gynecologic background | Parity | ||
| Yes | 23 (48.94%) | 27 (48.21%) | |
| No | - | 1 (1.79%) | |
| Not available | 24 (51.06%) | 28 (50.00%) | |
| Miscarriage | |||
| Yes | 7 (14.89%) | 15 (26.79%) | |
| No | 16 (34.05%) | 13 (23.21%) | |
| Not available | 24 (51.06%) | 28 (50.00%) | |
| Menopausal status | |||
| Premenopausal | 15 (38.30%) | 46 (82.14%) | |
| Postmenopausal | 18 (31.91%) | 2 (3.57%) | |
| Not available | 14 (29.79%) | 8 (14.29%) | |
| Symptoms | Pelvic mass | ||
| Yes | 25 (53.19%) | 28 (50.00%) | |
| No | 7 (14.89%) | 20 (35.71%) | |
| Not available | 15 (31.92%) | 8 (14.29%) | |
| Abnormal uterine bleeding | |||
| Yes | 17 (36.17%) | 26 (46.43%) | |
| No | 11 (23.40%) | 21 (37.50%) | |
| Not available | 19 (40.43%) | 9 (16.07%) | |
| Abdominal pain | |||
| Yes | 16 (34.04%) | 14 (25.00%) | |
| No | 11 (23.41%) | 32 (57.14%) | |
| Not available | 20 (42.55%) | 10 (17.86%) | |
| Imaging | CT | ||
| Yes | 14 (29.79%) | 7 (12.50%) | |
| No | 16 (34.04%) | 42 (75.00%) | |
| Not available | 17 (36.17%) | 7 (12.50%) | |
| MRI | |||
| Yes | 5 (10.64%) | 5 (8.93%) | |
| No | 22 (46.81%) | 44 (78.57%) | |
| Not available | 20 (42.55%) | 7 (12.50%) | |
| Ultrasound | |||
| Yes | 31 (65.96%) | 49 (87.50%) | |
| No | - | - | |
| Not available | 16 (34.04%) | 7 (12.50%) | |
| Tumor size (cm) | |||
| Median | 13 | 7.4 | |
| Range | mar-24 | 0.25–25 | |
| Not available (n) | 17 | 10 | |
| Suspected uterine sarcoma | |||
| Yes | 15 (31.91%) | 5 (8.93%) | |
| No | 15 (31.91%) | 44 (78.57%) | |
| NA | 17 (36.18%) | 7 (12.50%) | |
| Surgical treatment | Endometrial biopsy | ||
| Yes | 15 (31.91%) | 39 (69.64%) | |
| No | 17 (27.66%) | 10 (17.86%) | |
| Not available | 19 (40.43%) | 7 (12.50%) | |
| Primary surgery | |||
| Laparoscopic hysterectomy | 1 (2.13%) | 12 (21.43%) | |
| Laparoscopic myomectomy | - | 5 (8.93%) | |
| Laparotomic hysterectomy | 33 (70.21%) | 21 (37.50%) | |
| Laparotomic myomectomy | - | 11 (19.64%) | |
| Not available | 13 (27.66%) | 7 (12.50%) | |
| Clinical follow-up | Recurrence | ||
| Yes | 19 (40.43%) | 49 (87.50%) | |
| No | 9 (19.16%) | - | |
| Not available | 19 (40.43%) | 7 (12.50%) | |
| Status | |||
| Alive | 12 (25.53%) | 48 (85.71%) | |
| Deceased | 12 (25.53%) | - | |
| Not available | 23 (48.84%) | 8 (14.29%) | |
| Follow-up (months) | |||
| Median | 24 | - | |
| Range | 8–116 | - | |
| Not available (n) | 29 | - |